• BioAge Labs released a medical research presentation on Phase 1 results for BGE-102, an oral NLRP3 inhibitor studied in healthy volunteers and participants with obesity.
• Trial readouts showed 90% ex vivo IL-1β suppression at trough at 60 mg, rising to 98% at 120 mg after 14 days.
• In a 120 mg multiple-ascending-dose cohort in obesity, hsCRP fell 86% at Day 14 versus 43% on placebo; 93% reached hsCRP below 2 mg/L.
• Safety profile showed mild-to-moderate adverse events with no serious events, no discontinuations, no dose-limiting toxicities.
• Data package supports moving BGE-102 into proof-of-concept studies targeting metabolic and inflammatory conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief on June 07, 2026, and is solely responsible for the information contained therein.